XPH ETF Holdings

Holdings

Symbol	Grade	Price % Change	Allocation
CORT	B	-0.11	4.96
LBPH	A	0.00	4.12
BMY	B	0.06	4.11
ITCI	B	-1.06	4.01
JAZZ	B	1.59	3.94
VTRS	A	0.04	3.73
AXSM	B	0.40	3.59
EWTX	C	1.19	3.42
CTLT	D	0.00	3.41
ELAN	D	-0.19	3.35
PRGO	C	-0.92	3.35
RPRX	D	0.99	3.18
JNJ	D	0.10	3.17
ZTS	D	0.00	3.15
PFE	F	-0.28	3.07
LLY	F	-1.40	2.94
MRK	F	0.15	2.93
TARS	C	-1.67	2.81
OGN	F	0.48	2.58
SAVA	D	3.95	2.57
ARVN	F	1.81	2.53
PBH	A	0.27	2.50
SUPN	B	-0.58	2.15
AMPH	F	-0.32	2.02
PCRX	C	0.76	1.91
LGND	C	0.51	1.77
ANIP	D	1.21	1.54
COLL	F	1.88	1.48
OCUL	C	-2.51	1.44
AMRX	C	-0.71	1.33
MNMD	C	-4.50	1.23
HRMY	F	-0.15	1.22
WVE	C	0.18	1.17
HROW	D	0.32	1.17
INVA	D	-0.57	0.98
EYPT	D	0.00	0.94
LQDA	F	-1.24	0.89
PLRX	D	-0.08	0.87
FULC	F	1.24	0.85
ELVN	C	-1.14	0.64
NUVB	C	0.78	0.60
EOLS	F	0.40	0.52
PHAT	F	3.09	0.48
XERS	C	0.33	0.46

Represented by ETF Holdings

Keywords: Biopharmaceutical Pharmaceutical Medicine Pharmaceutical Products Pain S&P 500 Alzheimer's Disease Animal Health Life Sciences Biotechnology Depression Diabetes Disease Drugs Hypertension Medication Neuroscience Pharmacology Suspension Acid

Industries: Biotechnology Drug Manufacturers - Specialty & Generic Drug Manufacturers - Major Drug Manufacturers - General Medical Distribution

Recent News for SPDR S&P Pharmaceuticals ETF & its Holdings

Date	Stock	Title
Nov 21	VTRS	Viatris Inc. (VTRS) Management Presents at Jefferies London Healthcare Conference (Transcript)
Nov 21	HRMY	HARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES
Nov 21	JAZZ	Zymeworks, Jazz Pharmaceuticals Receive FDA's Accelerated Approval for Ziihera to Treat Biliary Tract Cancer
Nov 21	HROW	Harrow’s ImprimisRx Subsidiary Receives $34.9 Million Unanimous Jury Verdict Award in ImprimisRx, LLC v. OSRX, Inc.
Nov 21	JAZZ	Jazz and Zymeworks announce FDA approval of cancer therapy Ziihera
Nov 21	LLY	Eli Lilly, Verge announce milestones in ALS collaboration
Nov 21	LLY	Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop
Nov 21	JAZZ	Jazz Pharmaceuticals Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)
Nov 20	LLY	Jim Cramer on Eli Lilly and Company (LLY): ‘I’m Kind Of Blown Away’
Nov 20	ZTS	Zoetis Inc. (ZTS) Management presents at Jefferies London Healthcare Conference (Transcript)
Nov 20	PFE	CDC warns of an imminent spike in COVID, flu cases
Nov 20	MRK	Merck Foundation Announces $17 Million U.S. Initiative To Expand Access to High-Quality Cardiac Care
Nov 20	JNJ	Update: Market Chatter: Johnson & Johnson, Merck Cut Jobs in China
Nov 20	LLY	Eli Lilly in pact with Chinese biotech for novel weight loss therapy
Nov 20	MRK	Merck & Co., Inc. (MRK)’s Blockbuster Drugs: A Key Player in Ken Griffin’s Portfolio
Nov 20	PFE	5 Year-to-Date Laggards to Buy Amid Solid Near-Term Upside Potential
Nov 20	ANIP	ANI (ANIP) Upgraded to Buy: What Does It Mean for the Stock?
Nov 20	LLY	More companies covering weight loss drugs for their employees
Nov 20	LLY	Weight loss drug makers want more insurance plans to cover Wegovy and Zepbound
Nov 20	PFE	Pfizer Appoints Cancer Research Head Chris Boshoff as New R&D Chief

The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of an index derived from the pharmaceuticals segment of a U.S. total market composite index. In seeking to track the performance of the S&P Pharmaceuticals Select Industry Index (the "index"), the fund employs a replication strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the pharmaceuticals industry group of the S&P Total Market Index ("S&P TMI"). The fund is non-diversified.
Exchange Traded Fund ETF Index Fund S&P Top 100 Loan Index Pharmaceuticals Segment

ETF Components for XPH - SPDR S&P Pharmaceuticals ETF